Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias.

摘要: The benefit/risk profile offlecainide is not completely defined, particularly in patients with congestive heart failure, which can alter both drug pharmacokinetics and pharmacodynamics (Roden & Woosley 1986). Flecainide has a plasma half-life (t'l,) of about 20 hours ventricular arrhythmias (Woosley et al. Despite the effects failure on antiarrhythmic kinetics 1986), only slight increase flecainide was reported when given single oral dose (Franciosa 1983). We have observed an unexpected prolongation 2 marked left dysfunction, who were treated long term drug.